A Phase 3 interventional study of NOMAC-E2 COC in Contraception, sponsored by Organon and Co. Terminated at 103 sites in United States. Open to female participants aged 14 Years to 35 Years. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Organon and Co · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is evaluating Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive in Premenopausal Females Aged 14 to 35 Years (Inclusive).
This is a Phase 3, Open-label, Multi-center, Single-arm Study to Assess Contraceptive Efficacy and Safety of the Nomegestrol Acetate + 17β-estradiol Combined Oral Contraceptive (OG-8175A) in Premenopausal Females Aged 14 to 35 Years (Inclusive). Potential participants must be sexually active and engage in heterosexual vaginal intercourse at least once per month with a partner who is not known to be subfertile, sterilized, or infertile, and should not routinely use any other form of contraception.
A total of 2,680 fertile premenopausal women aged 14 to 35 years (inclusive) will be screened to achieve about 1,878 (with at least 657 participants with BMI ≥30 kg/m2) being allocated to study treatment. Over 1,000 total participants are expected to complete 1 year of treatment (13 cycles).
The total duration of study participation will be up to 60 weeks, which includes a Pre-treatment Period of approximately 6 weeks, a Treatment Period of 52 weeks, and a Follow-up Period of 2 weeks after the last intake of study drug.
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The NOMAC-E2 COC active tablets contain 2.5 mg NOMAC and 1.5 mg E2 and will be used in a 24/4 regimen, i.e., 28-day cycles with 24 days of active tablet intake followed by 4 days of placebo tablet intake.
Drug: NOMAC-E2 COC
Drug pages: Nomegestrol acetateStudies of Nomegestrol acetateNomegestrol acetate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · EstradiolStudies of EstradiolEstradiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Dosage Formulation: Film-coated Tablet Unit Dose Strength: Nomegestrol acetate (NOMAC) 2.5 mg and estradiol (E2) 1.5 mg; Each blister strip contains 28 tablets: 24 tablets with the active drug (number 1 to 24) and 4 tablets with placebo (number 25 to 28). Dosing Instructions: oral. Take 1 tablet daily at about the same time as directed.
Also known as: Nomegestrol acetate / estradiol
Number of Participants With On-treatment Pregnancies
Raw count of the number of pregnancies that occurred while participants were taking study drug
Time frame: 1 year
Proportion of Participants With an Adverse Event (Regardless on Potential Relationship to Study Drug)
Time frame: 1 year
Proportion of Participants Who Prematurely Discontinue Study Drug Treatment
Time frame: 1 year
Percentage of Participants With On-treatment Pregnancies With at Least One Completed Cycle
Number of participants with on-treatment pregnancies as a percentage of the number of participants with at least one completed cycle
Time frame: 1 year
Number of Cycles of Exposure Prior to Pregnancy
In participants who experienced on-treatment pregnancy, the mean number of completed treatment cycles prior to occurrence of the pregnancy (for participants with known date of conception)
Time frame: 1 year
Number of Participants With a Pregnancy, Based on Baseline BMI Categories (<30 kg/m2, ≥30 kg/m2)
Raw count of the number of pregnancies that occurred while participants were taking study drug in each BMI category
Time frame: 1 year
Proportion of Participants With Bleeding-spotting Days
Number of participants with bleeding-spotting days as a proportion of the number of participants who had at least one completed cycle
Time frame: 28-day cycles across one year
Mean Number of Bleeding and/or Spotting Days Per Cycle
For participants who had at least one completed cycle, the mean number of bleeding-spotting days per cycle
Time frame: 28-day cycles across one year
Average Number of Bleeding-spotting Days Per Reference Period
For participants with at least one completed reference period, the average number of bleeding-spotting days per reference period
Time frame: 91-day reference periods across one year
Proportion of Participants With 8 or More Bleeding-spotting Days
Proportion of participants who had at least one completed cycle with 8 or more bleeding-spotting days in a cycle
Time frame: 28-day cycles across one year
Mean NOMAC Concentration, Visit 3 Pre-Dose
NOMAC concentrations assessed through use of sparse sampling
Time frame: Treatment Week 5
Mean NOMAC Concentration, Visit 3 Post-Dose
NOMAC concentrations assessed through use of sparse sampling
Time frame: Treatment Week 5
Mean NOMAC Concentration, Visit 4 Pre-Dose
NOMAC concentrations assessed through use of sparse sampling
Time frame: Treatment Week 17
Mean NOMAC Concentration, Visit 4 Post-Dose
NOMAC concentrations assessed through use of sparse sampling
Time frame: Treatment Week 17
| Milestone | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| Started | 1919 |
| Completed | 402 |
| Not completed | 1517 |
| Withdrew: Adverse event | 59 |
| Withdrew: Lost to follow-up | 204 |
| Withdrew: Protocol violation | 185 |
| Withdrew: Pregnancy | 60 |
| Withdrew: Physician decision | 6 |
| Withdrew: Non-compliance with study drug | 29 |
| Withdrew: Study termination | 677 |
| Withdrew: Withdrawal by subject | 208 |
| Withdrew: Discontinued prior treatment | 89 |
Raw count of the number of pregnancies that occurred while participants were taking study drug
| Participants | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| Number of Participants With On-treatment Pregnancies | 57 |
| participants | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| Proportion of Participants With an Adverse Event (Regardless on Potential Relationship to Study Drug) | 485 |
| participants | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| Proportion of Participants Who Prematurely Discontinue Study Drug Treatment | 62 |
Number of participants with on-treatment pregnancies as a percentage of the number of participants with at least one completed cycle
| percentage of participants | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| Percentage of Participants With On-treatment Pregnancies With at Least One Completed Cycle | 3.1 |
In participants who experienced on-treatment pregnancy, the mean number of completed treatment cycles prior to occurrence of the pregnancy (for participants with known date of conception)
| completed cycles | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| Number of Cycles of Exposure Prior to Pregnancy | 4.2 ± 3.47 |
Raw count of the number of pregnancies that occurred while participants were taking study drug in each BMI category
| Participants | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| BMI <30 kg/m2 | 39 |
| BMI >=30 kg/m2 | 18 |
Number of participants with bleeding-spotting days as a proportion of the number of participants who had at least one completed cycle
| participants | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| Proportion of Participants With Bleeding-spotting Days | 1721 |
For participants who had at least one completed cycle, the mean number of bleeding-spotting days per cycle
| bleeding-spotting days | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| Mean Number of Bleeding and/or Spotting Days Per Cycle | 4.0 ± 3.44 |
For participants with at least one completed reference period, the average number of bleeding-spotting days per reference period
| bleeding-spotting days | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| Average Number of Bleeding-spotting Days Per Reference Period | 13.1 ± 8.54 |
Proportion of participants who had at least one completed cycle with 8 or more bleeding-spotting days in a cycle
| participants | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| Proportion of Participants With 8 or More Bleeding-spotting Days | 709 |
NOMAC concentrations assessed through use of sparse sampling
| ng/mL | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| Mean NOMAC Concentration, Visit 3 Pre-Dose | 32.26 ± 310.457 |
NOMAC concentrations assessed through use of sparse sampling
| ng/mL | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| Mean NOMAC Concentration, Visit 3 Post-Dose | 73.61 ± 742.410 |
NOMAC concentrations assessed through use of sparse sampling
| ng/mL | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| Mean NOMAC Concentration, Visit 4 Pre-Dose | 36.01 ± 229.607 |
NOMAC concentrations assessed through use of sparse sampling
| ng/mL | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| Mean NOMAC Concentration, Visit 4 Post-Dose | 58.01 ± 363.400 |
Collected over All AEs and SAEs were collected from the time of screening through the end of study/end of treatment visit, which was 14 to 19 days after the last intake of study drug, up to approximately 1 year, 1 month.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) | 0/1,830 (0%) | 10/1,830 (0.5%) | 0/1,830 (0%) |
| Event | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 3/1830 |
| Suicidal ideationPsychiatric disorders | 2/1830 |
| Burns third degreeInjury, poisoning and procedural complications | 1/1830 |
| Ligament ruptureInjury, poisoning and procedural complications | 1/1830 |
| HeadacheNervous system disorders | 1/1830 |
| ParaesthesiaNervous system disorders | 1/1830 |
| Bipolar disorderPsychiatric disorders | 1/1830 |
| Ovarian cyst rupturedReproductive system and breast disorders | 1/1830 |
| Deep Vein ThrombosisVascular disorders | 1/1830 |
| HypertensionVascular disorders | 1/1830 |
The Safety Analysis Set consists of all participants who took at least one dose of the study treatment.
| Age, Continuous(years) | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| Mean | 27.2 ± 4.99 |
| Sex: Female, Male(Participants) | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| Female | 1830 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| Hispanic or Latino | 1004 |
| Not Hispanic or Latino | 817 |
| Unknown or Not Reported | 9 |
| Race (NIH/OMB)(Participants) | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| American Indian or Alaska Native | 15 |
| Asian | 29 |
| Native Hawaiian or Other Pacific Islander | 6 |
| Black or African American | 356 |
| White | 1358 |
| More than one race | 34 |
| Unknown or Not Reported | 32 |
| Region of Enrollment(Participants) | Nomegestrol Acetate + 17β-estradiol (NOMAC-E2; OG-8175A) |
|---|---|
| United States | 1830 |
Showing the first 100 of 103 sites. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2022 to primary completion in Jan 2024, 22 months.
Results were first posted in Nov 2025, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nomegestrol acetate · Estradiol